Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Orthofix Medical (OFIX) EBITDA (2016 - 2025)

Orthofix Medical's EBITDA history spans 16 years, with the latest figure at $203.9 million for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 199.29% year-over-year to $203.9 million, compared with a TTM value of $118.9 million through Dec 2025, up 149.85%, and an annual FY2025 reading of $118.9 million, up 192.13% over the prior year.
  • EBITDA for Q4 2025 was $203.9 million at Orthofix Medical, up from -$23.1 million in the prior quarter.
  • The five-year high for EBITDA was $203.9 million in Q4 2025, with the low at -$205.3 million in Q4 2024.
  • Average EBITDA over 5 years is -$2.8 million, with a median of -$4.1 million recorded in 2021.
  • Year-over-year, EBITDA soared 388.37% in 2022 and then crashed 1204.46% in 2024.
  • Tracing OFIX's EBITDA over 5 years: stood at $68.8 million in 2021, then crashed by 48.89% to $35.2 million in 2022, then plummeted by 161.43% to -$21.6 million in 2023, then plummeted by 850.33% to -$205.3 million in 2024, then soared by 199.29% to $203.9 million in 2025.
  • Per Business Quant, the three most recent readings for OFIX's EBITDA are $203.9 million (Q4 2025), -$23.1 million (Q3 2025), and -$10.6 million (Q2 2025).